HONG KONG – In the same week that it started construction of the largest biological manufacturing facility in China, Wuxi Pharmatech Inc. also received a privatization proposal from its founder and chairman. Read More
SHANGHAI – China may not be known for innovation, but Generon Corp. Ltd.'s founders decided 12 years ago they were not going to let that stop them from developing a potentially first-in-class biologic: F-652, a recombinant protein containing human interleukin 22 (IL-22). Read More
HONG KONG – The findings of a Sino-U.S. study that links the aging process to the deterioration of heterochromatin could lead to methods of preventing and/or treating age-related diseases including cancer, diabetes and Alzheimer's disease, researchers reported in the May 1, 2015, issue of Science. Read More
HONG KONG – Taigen Biotechnology Co. Ltd. started the first clinical trials of its stem cell mobilizer drug, burixafor (TG-0054), in mainland China. It received regulatory clinical trial approval from the CFDA in 2013 for phase I and II trials as a chemotherapy sensitizer in combination with two chemotherapeutic agents for the treatment of leukemia. Read More
TAIPEI, TAIWAN – Syncore Biotechnology Co. Ltd. (subsidiary of Taipei-based Sinpharm Pharmaceutical Group) received approval from the FDA for its solid tumor oncology agent SB01 to begin a phase II trial for head and neck cancer. Read More
SHANGHAI – Beigene Co. Ltd. has three candidates currently in phase I trials in Australia and has revealed the science and possible indications behind the cancer compounds: BGB-283, a second generation inhibitor of B-RAF; BGB-290, a poly (ADP-ribose) polymerase (PARP) inhibitor, and BGB-3111, an inhibitor of Bruton tyrosine kinase (BTK). Read More
Peptidream Inc., of Tokyo, inked a multitarget discovery and optimization collaboration with Merck & Co. Inc., of Kenilworth, N.J. Peptidream will use its Peptide Discovery Platform System (PDPS) technology to generate macrocylic/constrained peptides against multiple targets of interest selected by Merck. Read More
TOKYO – Two biotech companies from Japan are pooling complementary resources and products to tackle the rising incidence of dementia in a country with an aging population. Read More
